NCT04592952: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
- State
- State not given
- Phase
- Phase 4
- People
- 400 planned
- Started
- 8 Oct 2020
- Primary completion
- 1 Aug 2025
- Arms
- Single-Arm
- Results
- None posted
- 8 Oct 2020: Trial started
- 19 Oct 2020: Trial registered